TIDMFARN
RNS Number : 9955O
Faron Pharmaceuticals Oy
12 February 2021
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH
AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH
SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS ONLY DIRECTED AT PERSONS IN THE UNITED
KINGDOM THAT ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE
2(E) OF REGULATION 2017/1129/EU AS INCORPORATED INTO UK DOMESTIC
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 THAT ARE
ALSO (I) INVESTMENT PROFESSIONALS FALLING WITHIN ARTICLE 19(5) OF
THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION)
ORDER 2005 (THE "ORDER") AND/OR (II) HIGH NET WORTH ENTITIES, AND
OTHER PERSONS TO WHOM IT MAY LAWFULLY BE COMMUNICATED, FALLING
WITHIN ARTICLE 49(2)(A) TO (E) OF THE ORDER (EACH SUCH PERSON BEING
REFERRED TO AS A "RELEVANT PERSON"). ACCORDINGLY, THIS ANNOUNCEMENT
AND ITS CONTENTS MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO
ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO
WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT
PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. PERSONS
INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO
INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS.
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Registration of Placing Shares with the Trade Register
Capitalised terms used in this announcement have the meanings
given to them in the announcement made on 11 February 2021
regarding the proposed issue and placing of new ordinary shares in
the Company (the "Launch Announcement") and the subsequent
announcement released at 7.00 a.m. GMT / 9.00 a.m. EET on 12
February 2021 (the "Pricing and Results Announcement"), unless the
context provides otherwise.
Company announcement, 12 February 2021 at 3:00 p.m. GMT / 5:00
p.m. EET
TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON,
AIM: FARN), the clinical stage biopharmaceutical company, has as
previously announced completed the Placing. The Company announced
the results of the Placing on 12 February 2021.
A total of 3,521,127 Placing Shares subscribed for in the
Placing have been issued and registered in the Trade Register today
on 12 February 2021. The Placing Shares confer a right to dividends
and other shareholder rights from their registration with the Trade
Register. Following the Placing, the aggregate number of ordinary
shares in the Company is 50,417,874. One ordinary share entitles to
one vote in the general meeting of the Company. The Company holds
no treasury shares.
Trading in the Placing Shares is expected to commence on First
North and AIM latest on or around 16 February 2021.
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Swedbank AB (publ), Finnish Branch, Financial Adviser
Mika Karikoski (Corporate Finance)
Phone: +358 (0)40 741 6959
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: + 44 207 213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 40 555 4727
Jukka Järvelä
Phone: +358 50 553 8990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel, Naina Zaman
Phone: +1 (212) 362-1200
E-mail: julie.seidel@sternir.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs. The Company currently has
a pipeline based on the receptors involved in regulation of immune
response in oncology and organ damage. Bexmarilimab is its
investigative precision immunotherapy with the potential to provide
permanent immune stimulation for difficult-to-treat cancers through
targeting myeloid function. A novel anti-Clever-1 humanised
antibody, bexmarilimab targets Clever-1 positive (Common Lymphatic
Endothelial and Vascular Endothelial Receptor 1) tumour associated
macrophages (TAMs) in the tumour microenvironment, converting these
highly immunosuppressive M2 macrophages to immune stimulating M1
macrophages. With the ability to switch immune suppression to
immune activation in various conditions, bexmarilimab has potential
across oncology, infectious diseases and vaccine development.
Currently in phase I/II clinical development as a potential therapy
for patients with untreatable solid tumours, bexmarilimab has
potential as a single-agent therapy or in combination with other
standard treatments including immune checkpoint molecules.
Traumakine is an investigational intravenous (IV) interferon
beta-1a therapy for the treatment of acute respiratory distress
syndrome (ARDS) and other ischemic or hyperinflammatory conditions.
In addition to its profound antiviral effect, Traumakine
upregulates the cell surface protein Cluster of Differentiation 73
(CD73), an enzyme that suppresses pro-inflammatory responses in
endothelial cells. Using an IV administration of interferon beta-1a
provides optimal exposure to the lung vasculature, increasing
protection against serious lung complications and helping to
prevent vascular leakage by enhancing endothelial barrier function.
Traumakine is currently being evaluated in global trials as a
potential treatment for hospitalised patients with COVID-19. As
part of a working relationship established with Faron, the 59th
Medical Wing of the US Air Force and the US Department of Defense
are also evaluating Traumakine's role in preventing multiple organ
dysfunction syndrome (MODS) after ischemia-reperfusion injury
caused by a major trauma. Faron is based in Turku, Finland. Further
information is available at www.faron.com .
IMPORTANT INFORMATION
Market Abuse Regulation
Market soundings, as defined in Regulation (EU) No 596/2014
("MAR"), were taken in respect of the proposed Placing with the
result that certain persons became aware of inside information, as
permitted by MAR. That inside information in relation to the
Placing is set out in this announcement and has been disclosed as
soon as possible in accordance with paragraph 7 of article 17 of
MAR. Therefore, those persons that received inside information in
such market sounding are no longer in possession of inside
information relating to the Company and its securities.
MiFID II
Solely for the purposes of the product governance requirements
contained within: (a) EU Directive 2014/65/EU on markets in
financial instruments, as amended ("MiFID II"); (b) Articles 9 and
10 of Commission Delegated Directive (EU) 2017/593 supplementing
MiFID II; and (c) local implementing measures (together, the "MiFID
II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which
any "manufacturer" (for the purposes of the MiFID II Product
Governance Requirements) may otherwise have with respect thereto,
the Placing Shares have been subject to a product approval process,
which has determined that the Placing Shares are: (i) compatible
with an end target market of: (a) retail investors, (b) investors
who meet the criteria of professional clients and (c) eligible
counterparties (each as defined in MiFID II); and (ii) eligible for
distribution through all distribution channels as are permitted by
MiFID II (the "Target Market Assessment"). Notwithstanding the
Target Market Assessment, distributors should note that: the price
of the Placing Shares may decline and investors could lose all or
part of their investment; the Placing Shares offer no guaranteed
income and no capital protection; and an investment in the Placing
Shares is compatible only with investors who do not need a
guaranteed income or capital protection, who (either alone or in
conjunction with an appropriate financial or other adviser) are
capable of evaluating the merits and risks of such an investment
and who have sufficient resources to be able to bear any losses
that may result therefrom. The Target Market Assessment is without
prejudice to the requirements of any contractual, legal or
regulatory selling restrictions in relation to the offer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEDZGMZDZDGMZM
(END) Dow Jones Newswires
February 12, 2021 10:00 ET (15:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024